Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Allergo Journal
Literatur
1.
Durham SR, Shamji MH. Allergen immunotherapy: past, present and future. Nat Rev Immunol 2023,23:317-28
2.
Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy 2018,73:765-98
3.
Penagos M, Durham SR. Duration of allergen immunotherapy for inhalant allergy. Curr Opin Allergy Clin Immunol 2019,19:594-605
4.
Creticos PS, Gunaydin FE, Nolte H, Damask C, Durham SR. Allergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Forms of Immunotherapy for Allergic Rhinitis/Conjunctivitis and Asthma. J Allergy Clin Immunol Pract 2024
5.
Banatwala U, Nasir MM, Javed R, Ahmed A, Farhan SA, Ajam A. From Skin to Solution: Exploring Epicutaneous Immunotherapy for Peanut Allergy-A Systematic Review and Meta-Analysis. Clin Rev Allergy Immunol 2024,66:125-37
6.
Dupont C, Burks AW, Fleischer DM, Bee KJ, Chainani S, Sampson HA. Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy. Expert Rev Clin Immunol 2024,20:623-33
7.
Senti G, Freiburghaus AU, Larenas-Linnemann D, Hoffmann HJ, Patterson AM, Klimek L et al. Intralymphatic Immunotherapy: Update and Unmet Needs. Int Arch Allergy Immunol 2019,178:141-9
8.
Hoffmann HJ, Hviid-Vyff B. Strengthening the case for intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol 2022,22:387-95
9.
Todoric K, Merrill S. Oral Immunotherapy: An Overview. Med Clin North Am 2024,108:719-31
10.
Noon L. Prophylactic inoculation against hay fever. Lancet 1911,1:1572-3
11.
Cooke RA, Barnard JH, Hebald S, Stull A. Serological Evidence of Immunity with Coexisting Sensitization in a Type of Human Allergy (Hay Fever). J Exp Med 1935,62:733-50
12.
Loveless MH. Immunological studies of pollinosis: I. The presence of two antibodies related to the same pollen-antigen in the serum of treated hay-fever patients. Journal of Immunology 1940,38:25-50
13.
Loveless MH. Immunological studies of pollinosis IV. The relationship between thermostable antibody in the circulation and clinical immunity. Journal of Immunology 1943,47:165-80
14.
Lessof MH, Sobotka AK, Lichtenstein LM. Effects of passive antibody in bee venom anaphylaxis. Johns Hopkins Med J 1978,142:1-7
15.
Djurup R, Osterballe O. IgG subclass antibody response in grass pollen-allergic patients undergoing specific immunotherapy. Prognostic value of serum IgG subclass antibody levels early in immunotherapy. Allergy 1984,39:433-41
16.
Djurup R. The subclass nature and clinical significance of the IgG antibody response in patients undergoing allergen-specific immunotherapy. Allergy 1985,40:469-86
17.
Nakagawa T, Kozeki H, Katagiri J, Fujita Y, Yamashita N, Miyamoto T et al. Changes of house dust mite-specific IgE, IgG and IgG subclass antibodies during immunotherapy in patients with perennial rhinitis. Int Arch Allergy Appl Immunol 1987,82:95-9
18.
Peng ZK, Naclerio RM, Norman PS, Adkinson NF, Jr. Quantitative IgE- and IgG-subclass responses during and after long-term ragweed immunotherapy. J Allergy Clin Immunol 1992,89:519-29
19.
Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003,132:13-24
20.
Gehlhar K, Schlaak M, Becker W, Bufe A. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 1999,29:497-506
21.
Shamji MH, Ljorring C, Francis JN, Calderon MA, Larche M, Kimber I et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012,67:217-26
22.
Wurtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy 2008,38:1290-301
23.
Petersen AB, Gudmann P, Milvang-Gronager P, Morkeberg R, Bogestrand S, Linneberg A et al. Performance evaluation of a specific IgE assay developed for the ADVIA centaur immunoassay system. Clin Biochem 2004,37:882-92
24.
Shamji MH, Wilcock LK, Wachholz PA, Dearman RJ, Kimber I, Wurtzen PA et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006,317:71-9
25.
Kleine Budde I, de Heer PG, van der Zee JS, Aalberse RC. The stripped basophil histamine release bioassay as a tool for the detection of allergen-specific IgE in serum. Int Arch Allergy Immunol 2001,126:277-85
26.
Atanasio A, Franklin MC, Kamat V, Hernandez AR, Badithe A, Ben LH et al. Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response. J Allergy Clin Immunol 2022,149:200-11
27.
Orengo JM, Radin AR, Kamat V, Badithe A, Ben LH, Bennett BL et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun 2018,9:1421
28.
Shamji MH, Singh I, Layhadi JA, Ito C, Karamani A, Kouser L et al. Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. Am J Respir Crit Care Med 2021,204:23-33
29.
de Blay FJ, Gherasim A, Domis N, Meier P, Shawki F, Wang CQ et al. REGN1908/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unit. J Allergy Clin Immunol 2022,150:1437-46
30.
Gevaert P, De Craemer J, De Ruyck N, Rottey S, de Hoon J, Hellings PW et al. Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study. J Allergy Clin Immunol 2022,149:189-99
31.
Atanasio A, Orengo JM, Sleeman MA, Stahl N. Biologics as novel therapeutics for the treatment of allergy: Challenges and opportunities. Front Allergy 2022,3:1019255
32.
Zha L, Leoratti FMS, He L, Mohsen MO, Cragg M, Storni F et al. An unexpected protective role of low-affinity allergen-specific IgG through the inhibitory receptor FcgammaRIIb. J Allergy Clin Immunol 2018,142:1529-36 e6
33.
Strobl MR, Demir H, Stadlmayr G, Stracke F, Hoelzl R, Bohle B et al. Affinity matters for IgE-blocking activity of allergen-specific antibodies. Allergy 2023,78:2543-6
34.
Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004,172:3252-9
35.
Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009,39:469-77
36.
Ejrnaes AM, Bodtger U, Larsen JN, Svenson M. The blocking activity of birch pollen-specific immunotherapy-induced IgG4 is not qualitatively superior to that of other IgG subclasses. Mol Immunol 2004,41:471-8
37.
Zinkhan S, Thoms F, Augusto G, Vogel M, Bachmann MF. On the role of allergen-specific IgG subclasses for blocking human basophil activation. Front Immunol 2022,13:892631
38.
Subbarayal B, Schiller D, Mobs C, de Jong NW, Ebner C, Reider N et al. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen. Allergy 2013,68:1377-86
39.
Strobl MR, Demir H, Sanchez Acosta G, Drescher A, Kitzmuller C, Mobs C et al. The role of IgG(1) and IgG(4) as dominant IgE-blocking antibodies shifts during allergen immunotherapy. J Allergy Clin Immunol 2023,151:1371-8 e5
40.
Kinaciyan T, Nagl B, Faustmann S, Frommlet F, Kopp S, Wolkersdorfer M et al. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy. J Allergy Clin Immunol 2018,141:1002-8
41.
Sanchez Acosta G, Kinaciyan T, Kitzmuller C, Mobs C, Pfutzner W, Bohle B. IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy. J Allergy Clin Immunol 2020,146:894-900 e2
42.
Grilo JR, Kitzmuller C, Aglas L, Sanchez Acosta G, Vollmann U, Ebner C et al. IgE-cross-blocking antibodies to Fagales following sublingual immunotherapy with recombinant Bet v 1. Allergy 2021,76:2555-64
43.
Devey ME, Bleasdale-Barr KM, Bird P, Amlot PL. Antibodies of different human IgG subclasses show distinct patterns of affinity maturation after immunization with keyhole limpet haemocyanin. Immunology 1990,70:168-74
44.
Chen G, Shrock EL, Li MZ, Spergel JM, Nadeau KC, Pongracic JA et al. High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy. Cell Rep Med 2021,2:100410
45.
Hoof I, Schulten V, Layhadi JA, Stranzl T, Christensen LH, Herrera de la Mata S et al. Allergen-specific IgG(+) memory B cells are temporally linked to IgE memory responses. J Allergy Clin Immunol 2020,146:180-91.
46.
James LK, Shamji MH, Walker SM, Wilson DR, Wachholz PA, Francis JN et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011,127:509-16 e1-5
47.
Shamji MH, Valenta R, Jardetzky T, Verhasselt V, Durham SR, Wurtzen PA et al. The role of allergen-specific IgE, IgG and IgA in allergic disease. Allergy 2021,76:3627-41
48.
Eguiluz-Gracia I, Parkin RV, Layhadi JA, Palmer E, Meng X, Zhu R et al. Nasal allergen-neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis. Allergy 2024;79:2197-206
49.
He Y, Liu J, Zhao D, Zhang S, Hao G, Sun Y et al. The IgE Blocking Activity Induced by Dermatophagoides pteronyssinus Subcutaneous Immunotherapy Does Not Correlate with Specific IgA but with IgG4 in both Serum and Saliva. Int Arch Allergy Immunol 2021,182:1231-44
50.
Kepley CL, Cambier JC, Morel PA, Lujan D, Ortega E, Wilson BS et al. Negative regulation of FcepsilonRI signaling by FcgammaRII costimulation in human blood basophils. J Allergy Clin Immunol 2000,106:337-48
51.
van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999,163:2944-52
Metadaten
Titel
The role of IgG1 and IgG4 as dominant IgE-blocking antibodies during allergen immunotherapy
verfasst von
Prof. Dr. med. Barbara Bohle
Publikationsdatum
12.12.2024
Verlag
Springer Medizin
Erschienen in
Allergo Journal / Ausgabe 8/2024
Print ISSN: 0941-8849
Elektronische ISSN: 2195-6405
DOI
https://doi.org/10.1007/s15007-024-6398-7

Weitere Artikel der Ausgabe 8/2024

Buchtipp: „Allergie kurz und knapp“

Biomarker-basierte personalisierte Medizin in der Allergologie

Requirements for regulatory acceptance of biomarkers

Änderung des Einheitlichen Bewertungsmaßstabs ab Januar 2025

  • EBM
  • Verbandsmitteilung

Leserbrief: Präparatewechsel bei der AIT

Reizende Gartenarbeit

Neu im Fachgebiet HNO

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Kopf-Hals-Tumore: Lebensqualität von Langzeitüberlebenden

Eine aktuelle Studie des Universitätsklinikums Erlangen verdeutlicht, dass Langzeitüberlebende von Kopf-Hals-Tumoren eine geringe Symptomlast aufweisen. Die am häufigsten auftretenden Beschwerden – Müdigkeit, Angstzustände, Schläfrigkeit und Schmerzen – sollten von den behandelnden Ärztinnen und Ärzten gezielt adressiert werden.

Schlafapnoe – es lag an einer verbogenen Nasenscheidewand

Tritt eine obstruktive Schlafapnoe vor allem in einer bestimmten Seitenlage auf, kann dies auch an einem verbogenen Nasenseptum liegen. Eine Septumplastik lindert die Beschwerden mitunter deutlich.

Das alles ändert sich für Arztpraxen in 2025

  • 31.12.2024
  • EBM
  • Nachrichten

Ab Januar greifen jede Menge Neuerungen – ob im EBM, Arbeits- und Steuerrecht oder bei der digitalen Vernetzung. Darunter einige Verbesserungen, aber teils auch Mehraufwand. „Same procedure as every year?“ – Ein Überblick.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise